Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity

Bibliography

• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91
   PubMed Web of Science ®Google Scholar
• Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
   PubMed Web of Science ®Google Scholar
• Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628-36
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098
   PubMed Web of Science ®Google Scholar
• White WB, Cruz C. Impact of NSAIDs on cardiovascular risk and hypertension. Italian J Med 2011;5:175-83
   Google Scholar
• García Rodríguez LA, González-Pérez A, Bueno H, Hwa J. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS ONE 2011;6:e16780
   PubMed Web of Science ®Google Scholar
• Fosbol EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDS) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009;85:190-7
   PubMed Web of Science ®Google Scholar
• Olsen AS, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction. A nationwide cohort study. Circulation 2011;123:2226-35
   PubMed Web of Science ®Google Scholar
• Ruana CH, Sob SP, Ruanb KH. Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease. Life Sci 2011;88:24-30
   PubMed Web of Science ®Google Scholar
• Kirkby NS, Lundberg MH, Harrington LS, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci USA 2012;109:17597-602
   PubMed Web of Science ®Google Scholar
• Pietro Minuz P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. Is prostacyclin inhibition the key event? J Am Coll Cardiol 2008;52:1637-9
   PubMed Web of Science ®Google Scholar
• Rudic RD, Brinster D, Cheng Y, et al. COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005;96:1240-7
   PubMed Web of Science ®Google Scholar
• Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005;111:334-42
   PubMed Web of Science ®Google Scholar
• Rabausch K, Bretschneider E, Sarbia M, et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 2005;96:e1-6
   PubMed Web of Science ®Google Scholar
• Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002;55:506-19
   PubMed Web of Science ®Google Scholar
• Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112:759-70
   PubMed Web of Science ®Google Scholar
• Singh BK, Pillai KK, Haque SE, Dubey K. Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. J Cardiovasc Pharmacol 2010;55:139-44
   PubMed Web of Science ®Google Scholar
• Oitate M, Hirota T, Takahashi M, et al. Mechanism for covalent binding of rofecoxib to elastin of rat aorta. J Pharmacol Exp Ther 2007;320:1195-203
   PubMed Web of Science ®Google Scholar
• Virdis A, Colucci R, Fornai M, et al. Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2005;312:945-53
   PubMed Web of Science ®Google Scholar
• Steffel J, Hermann M, Greutert H, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005;111:1685-9
   PubMed Web of Science ®Google Scholar
• Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006;79:9-19
   PubMed Web of Science ®Google Scholar
• Wheal AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol 2007;152:717-24
   PubMed Web of Science ®Google Scholar
• Sudano I, Flammer AJ, Pe´riat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122:1789-96
   PubMed Web of Science ®Google Scholar
• Sudano I, Flammer AJ, Roas S, et al. Nonsteroidal anti-inflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep 2012;14:304-9
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, Zoppi A, Mugellini A, et al. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan andaliskiren in hypertensive patients. Expert Opin Pharmacother 2013;14:1875-84
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11
   PubMed Web of Science ®Google Scholar
• Moreno-Sánchez R, Bravo C, Vásquez C, et al. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999;57:743-52
   PubMed Web of Science ®Google Scholar
• Cocco T, Di Paola M, Papa S, Lorusso M. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. Free Radic Biol Med 1999;27:51-9
   PubMed Web of Science ®Google Scholar
• Sowers JR, White WB, Pitt B, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-h blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8
   PubMed Web of Science ®Google Scholar
• Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300
   PubMed Web of Science ®Google Scholar
• Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6
   PubMed Web of Science ®Google Scholar
• Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000;13:1161-7
   PubMed Web of Science ®Google Scholar
• Wang D, Patel VV, Ricciotti E, et al. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA 2009;106:7548-52
   PubMed Web of Science ®Google Scholar
• Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-70
   PubMed Web of Science ®Google Scholar
• Vega J, Goecke H, Méndez GP, Guarda FJ. Nephrotic syndrome and acute tubular necrosis due to meloxicam use. Ren Fail 2012;34:1344-7
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50-61
   PubMed Web of Science ®Google Scholar
• Qi Z, Cai H, Morrow JD, Breyer MD. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension 2006;48:323-8
   PubMed Web of Science ®Google Scholar
• Knights KM, Winner LK, Elliot DJ, et al. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 2009;68:402-12
   PubMed Web of Science ®Google Scholar
• Krum H, Swergold G, Gammaitoni A, et al. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther 2012;30:342-50
   PubMed Web of Science ®Google Scholar
• White WB, Kent J, Taylor A, et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39:929-34
   PubMed Web of Science ®Google Scholar
• Izhar M, Alausa T, Folker A, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004;43:573-7
   PubMed Web of Science ®Google Scholar
• Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63
   PubMed Web of Science ®Google Scholar
• Houston MC, Weir M, Gray J, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995;155:1049-54
   PubMed Web of Science ®Google Scholar
• White WB, Schnitzer TJ, Bakris GL, et al. Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol 2011;107:1338-45
   PubMed Web of Science ®Google Scholar
• Townsend R, Bittar N, Rosen J, et al. Blood pressure effects of naproxcinod in hypertensive patients. J Clin Hypertens (Greenwich) 2011;13:376-84
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Center for Drug Evaluation and Research. Joint Meeting of the Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM), 2010 FDA Web site: spaulding, M.D., M.P.H. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm212680.pdf [Accessed on 12 October 2013]
   Google Scholar
• Baerwald C, Verdecchia P, Duquesroix B, et al. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum 2010;62:3635-44
   PubMed Web of Science ®Google Scholar
• White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81
   PubMed Web of Science ®Google Scholar
• Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173-09
   PubMed Web of Science ®Google Scholar
• Cryer B, Li C, Simon LS, et al. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 2013;108:392-400
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84
   PubMed Web of Science ®Google Scholar
• Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95
   PubMed Web of Science ®Google Scholar
• Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35
   PubMed Web of Science ®Google Scholar
• ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33
   PubMedGoogle Scholar
• Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357:360-9
   PubMed Web of Science ®Google Scholar
• Pathan RA, Singh BK, Pillai KK, Dubey K. Naproxen aggravates doxorubicin-induced cardiomyopathy in rats. Indian J Pharmacol 2010;42:44-9
   PubMed Web of Science ®Google Scholar
• Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001;108:585-90
   PubMed Web of Science ®Google Scholar
• Zaitone SA, Moustafa YM, Mosaad SM, El-Orabi NF. Effect of evening primrose oil and omega-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats. J Cardiovasc Pharmacol 2011;58:72-9
   PubMed Web of Science ®Google Scholar
• Li H, Hortmann M, Daiber A, et al. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther 2008;326:745-53
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011;123:2226-35
   PubMed Web of Science ®Google Scholar
• Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3:395-405
   PubMed Web of Science ®Google Scholar
• Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169:141-9
   PubMed Web of Science ®Google Scholar
• Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009;2:155-63
   PubMed Web of Science ®Google Scholar
• Roumie CL, Choma NN, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf 2009;18:1053-63
   PubMed Web of Science ®Google Scholar
• Hammad TA, Graham DJ, Staffa JA, et al. Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2008;17:315-21
   PubMed Web of Science ®Google Scholar
• van Staa TP, Rietbrock S, Setakis E, Leufkens HG. Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction? J Intern Med 2008;264:481-92
   PubMed Web of Science ®Google Scholar
• Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87
   PubMed Web of Science ®Google Scholar
• Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906-13
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Stürmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006;54:1378-89
   PubMed Web of Science ®Google Scholar
• Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23
   PubMed Web of Science ®Google Scholar
• van der Linden MW, van der Bij S, Welsing P, et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2009;68:668-73
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Jick H. Diclofenac and acute myocardial infarction in patients with no major risk factors. Br J Clin Pharmacol 2007;64:662-7
   PubMed Web of Science ®Google Scholar
• Hudson M, Rahme E, Richard H, Pilote L. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective cyclooxygenase 2 inhibitors: a class effect? Arthritis Rheum 2007;57:516-23
   PubMed Web of Science ®Google Scholar
• Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113:1950-7
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006;27:1657-63
   PubMed Web of Science ®Google Scholar
• McGettigan P, Han P, Henry D. Cyclooxygenase-2 inhibitors and coronary occlusion-exploring dose-response relationships. Br J Clin Pharmacol 2006;62:358-65
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-84
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109:3000-6
   PubMed Web of Science ®Google Scholar
• White WB, Campbell P. Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed? Circulation 2010;122:1779-81
   PubMed Web of Science ®Google Scholar
• Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162:2204-8
   PubMed Web of Science ®Google Scholar
• Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7
   PubMed Web of Science ®Google Scholar
• Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167:394-09
   PubMed Web of Science ®Google Scholar
• Dawson J, Fulton R, McInnes GT, et al. Acetaminophen use and change in blood pressure in a hypertensive population. J Hypertens 2013;31:1485-90
   PubMed Web of Science ®Google Scholar